CAR-T cell therapy for hard-to-treat kidney disease
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new CAR-T cell treatment for children and adults with steroid-resistant nephrotic syndrome (SRNS), a kidney condition that doesn't get better with standard medicines. The goal is to see if this therapy can help improve kidney function when other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 2 or older.
- You must have steroid-resistant nephrotic syndrome that hasn't improved after at least 12 months of two different hormone-sparing medicines, or after 3-6 months of one calcineurin inhibitor.
- A kidney biopsy must show minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS).
- Your heart, kidneys, liver, and lungs must be working well enough (heart pump strength at least 55%, kidney function at least 30% of normal, liver enzymes less than 3 times normal, oxygen level at least 92%).
- You must not have had CAR-T or similar gene therapy before, and no active infections like hepatitis B, C, HIV, or CMV.
- You cannot be pregnant, and if you could become pregnant, you must use effective birth control for one year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This trial tests a new type of cell therapy, called BCMA/CD70 CAR-T, for children with lupus that hasn't improved with standard treatments. The goal is to see if it can safely reduce disease activity.
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Hear when a new Multi-Drug Resistant Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.